Background-There have been significant bidirectional changes in the prevalence of cardiovascular (CV) risk factors over time in the United States, making the net trend in risk for incident CV disease unknown. We assessed these trends by applying the Framingham Heart Study prediction model to national data. are cross-sectional representative samples of the noninstitutionalized population of the United States. We excluded people with a history of CV disease, pregnant women, participants with missing CV risk factors data, and individuals outside the Framingham age range of 30 to 74 years. The Framingham risk function was used to estimate the 10-year risk for incident symptomatic CV disease. We calculated the slope of change or rate of change per year between NHANES II and III, and between NHANES III and 1999 -2004. The difference between slopes was calculated and compared to zero. The average age-adjusted 10-year CV risk between NHANES II and III decreased from 10.0% to 7.9% between NHANES II and III, with a statistically significant slope (PϽ0.001). However, the average age-adjusted CV risk decreased at a lesser magnitude between NHANES III and NHANES 1999 -2004 from 7.9% to 7.4% (PϽ0.001). These slopes were significantly different (PϽ0.0001). In women and middle-aged participants, CV risk did not change between NHANES III and NHANES 1999 -2004 (Pϭ0.40). Conclusions-The estimated net risk for CV disease in the US population decreased from 1976 -1980 to 1988 -1994 but has changed minimally from 1988 -1994 to 1999 -2004, particularly in women and middle-aged people. (Circ Cardiovasc Qual Outcomes. 2009;2:443-450.)
C ardiovascular (CV) disease represents the most common cause of death in the United States, accounting for approximately 1 million deaths annually. 1 Multiple reports have demonstrated significant changes in the prevalence of CV risk factors over the last 30 years, including downward trends in cholesterol 2 and cigarette smoking, 3, 4 and an early decrease in the prevalence of hypertension for the last 10 years. [5] [6] [7] [8] [9] There have also been increases in the prevalence of obesity 10, 11 and diabetes mellitus. [12] [13] [14] Because these major CV risk factors provide different strengths of risk for incident myocardial infarction, 15 it is unknown whether the net trend in risk for incident CV disease in the United States has increased, decreased, or has remained stable over the last 3 decades.
Epidemiological studies assessing the trend in CV disease incidence has demonstrated conflicting results in the incidence of myocardial infarction or coronary artery disease as a whole. 16 The ascertainment of temporal trends in incident CV disease is difficult. Major challenges include change in the diagnostic criteria for myocardial infarction, changes in physicians practice, the discovery of new methods in diagnosing preclinical coronary disease, and the discovery and wide implementation of highly sensitive techniques in detecting myocardial injury. Despite the overwhelming evidence demonstrating a decrease in age-adjusted CV mortality over the last decades, [17] [18] [19] it is unclear whether the bidirectional trends in CV risk factors are reflected in a reduced risk for incident CV disease.
Validated risk prediction formulas can estimate individual coronary risk. 20 The formulas or algorithms are based on predictive modeling, which has been extensively validated in different populations in the United States 20, 21 and elsewhere. 22, 23 These prediction formulas provide reliable estimates of global population risk and help in identifying changes in net CV risk.
Using data from 3 consecutive population-based health surveys in the United States over the past 30 years, we assessed the trends in the net 10-year-risk for incident CV disease using the Framingham Coronary Heart Disease risk score. 20 We hypothesized that 10-year risk for incident CV disease has decreased between 1976 -1980 and 1988 -1994, but remained unchanged between 1988 -1994 and 1999 -2004 because of the significant increase in the prevalence of obesity and obesity-related CV risk factors.
WHAT IS KNOWN
• Cardiovascular disease represents the most common cause of death in the United States. • Hypertension and dyslipidemia have been well controlled through primary prevention measures. • An increasing prevalence of diabetes and obesity has paralleled this decline. • Validated cardiovascular risk prediction formulas can estimate individual coronary risk.
WHAT THE STUDY ADDS
• Cardiovascular risk factors have changed at different rates in the past 30 years. • The net 10-year risk for incident cardiovascular disease in the United States decreased significantly from 1976 -1980 to 1990 -1994 but changed minimally thereafter. • Impact of diminishing change in risk is likely attributable to slower improvements in lipid management and smoking rates but probably due to the effect of an increasing prevalence of diabetes and obesity.
Methods

Study Population
The National Health and Nutrition Examination Survey (NHANES) are 3 cross-sectional surveys representative of noninstitutionalized people in the United States. The present analysis incorporated major CV risk factors from NHANES II (1976 -1980) , NHANES III (1988 , and NHANES 1999 -2004, all collected in a standardized manner. Detailed study design and sampling have been described previously. 24 -30 Because our focus was to estimate the 10-year risk for incident CV disease, we excluded people with a self-reported history of myocardial infarction, angina, or stroke; pregnant women; people with missing CV risk factor data; individuals Ͼ74 years as they were not included in NHANES II; and subjects Ͻ30 years as the Framingham score was not designed to assess risk in this age group. Of participants with nonzero weights, we excluded 2310 participants of a total of 9237 in NHANES II, 1800 participants of 11 137 from NHANES III, and 1836 participants of 9702 from NHANES 1999 -2004. There were a total of 6927 participants, 9337 participants, and 7866 participants used from each respective survey in the risk function. The subset of patients with fasting data included 3463 patients for NHANES II, 4494 from NHANES III, and 7866 from NHANES 1999 -2004. NHANES III and NHANES 1999 -2004 underwent formal institutional review board approval, which included a written informed consent. NHANES II did not have formal institutional review in the manner in which it is defined currently. This analysis obtained an exemption from the Institutional Review Board as the data were deidentified in nature.
Measurements
Lipid analyses were conducted on frozen serum samples shipped on dry ice to a central laboratory. 31 Cholesterol measurements were standardized according to the Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program criteria. 31 We used different definitions of dyslipidemia depending of the parameter used and history of treatment. High cholesterol was defined as a measured total cholesterol (TChol) Ն240 mg/dL. Dyslipidemia was defined as participants having a total cholesterol (TChol) Ն240 mg/dL, or a high-density lipoprotein cholesterol (HDL) Յ40 mg/dL in men or Յ50 mg/dL in women. Finally, "Dyslipidemia with TG" included participants with a diagnosis of dyslipidemia with a triglyceride (TG) level of Ն150 mg/dL whose blood results were based on a morning subsample of blood. We also classified participants according to the history of self-reported dyslipidemia and treatment for it. These definitions paralleled those outlined by the National Cholesterol Education Program Adult Treatment Panel III guidelines. 32 Plasma glucose was measured using the hexokinase enzymatic method. 13, 33 Diabetes prevalence was defined as the sum of the number or participants with self-reported diabetes on the whole sample combined with those with glucose level Ն126 mg/dL on the fasting morning subsample using methods of Flegal et al, 34 and termed "prevalent diabetes." This calculation includes variance calculations using jackknife methods accounting for dependence between the two samples. 34, 35 This definition of diabetes was based on the most recent American Diabetes Association consensus statement 36 and was slightly different from the definition used in the Framingham study, 20 where the cutoff value for fasting glucose was 150 mg/dL. However, the CV risk associated with a fasting glucose between 126 to 150 is very similar to the risk of glucose values just above 150 mg/dL. Undiagnosed diabetes was defined as a fasting glucose of Ն126 mg/dL 36 and absence of self-reported diabetes.
Differences in blood pressure measurement protocol across the 3 surveys included the number of measurements, the qualifications of the staff performing them, and whether it was measured in seated or supine positions. We limited our analysis to sitting measurements. The first measurement was excluded unless it was the only one available, and the remaining measurements were averaged to conform to procedures used in NHANES 1999 -2004. We defined "history of hypertension" as a self-reported diagnoses of hypertension and defined "hypertension-measured" if systolic blood pressure was Ն140 mm Hg or diastolic blood pressure was Ն90 mm Hg, regardless of the presence of self-reported hypertension or current hypertension treatment. This was performed in line with the manner the Framingham 10-year risk score incorporates blood pressure values. This model does not differentiate between diagnosed versus undiagnosed hypertension, or between those receiving treatment for hypertension versus those untreated. We also analyzed the prevalence of treated hypertension.
Current smoking was defined as current cigarette, pipe, or cigar smoker. Current cigarette smoking was defined if subjects answered yes to both questions: "Have you smoked at least 100 cigarettes in your entire life?" and "Do you smoke cigarettes now?" Current cigar or pipe smoking was defined if participants smoked either type "every day" or "some days." The NHANES definition of current smoking was slightly different from the Framingham study, 20 where current smoking was defined as smoking regularly during the previous 12 months.
Weight and height were measured by standard protocols. Body mass index (BMI) was calculated by dividing the weight in kilograms by the square of height in meters. Obesity was defined as BMI Ն30kg/m 2 .
NHANES Data
Data and documentation for all surveys were downloaded in September/October 2006 from the NHANES website. 37 Combined sampling weights for NHANES 1999 -2004 were created according to guidelines. 38 Age groups consisting of ages 30 to 40, 40 to 50, and 60 to 74 were defined for trend comparisons as recommended by NHANES III. 39
Coronary Heart Disease Risk Function
We used the Framingham formula 20 to estimate the 10-year risk for incident coronary disease, separately by sex, using age, TChol, HDL, blood pressure (5 categories each), diabetes (yes/no), and smoking (yes/no). The crude score was calculated based on the linear function consisting of the sum of ␤ coefficients and transformed into 10-year predicted CV disease risk. The risk score was used in statistical tests of change as it had a less skewed distribution than the 10-year risk itself. CV risk was additionally calculated as if all members were 50 years old.
Analysis
We calculated weighted means, standard errors, and 95% confidence limits using SAS-callable SUDAAN 9.0.1 to properly account for the complex survey design. The NHANES examination sample weight was used for most variables. The morning fasting sample weight was used for the subsample with values for fasting glucose, low-density lipoprotein cholesterol (LDL), and TGs. Triglyceride values were converted to their natural log during the analyses because of the considerable skewness of the variable.
Results were age-sex standardized by the direct method to the actual results of the US Census 2000 population. 40, 41 We did not use the Year 2000 age-adjustment weights that are commonly used in mortality estimates, because these weights are based on the predicted US population in year 2000 and not on actual values. The age groups used for standardization were 30 to 40, 40 to 49, 50 to 59, and 60 to 74 years. This standardization also served to adjust for missing data by age and sex. For trend analyses we used F tests. Our primary outcome was the slope of change or rate of change per year between NHANES II and III (first time period), and between NHANES III and 1999 -2004 (second time period). For each survey we used the time frame between the midpoints to measure the elapsed time between surveys, using 13 years as the average time between the first 2 surveys and 10.5 years between the last 2. The difference in slopes was also calculated and compared to zero using a t test. A probability value Ͻ0.05 was considered statistically significant. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
The Table represents the general characteristics of participants during the 3 NHANES surveys, standardized to the US 2000 Census, and demonstrates the change in slope between NHANES II and NHANES III and between NHANES III and NHANES 1999 -2004 and the difference between the slopes. 
Obesity
The prevalence of obesity rose during each time period, a trend similar in both sexes. The mean BMI increased in all age groups, as did the proportion with a BMI Ն30 kg/m 2 , but the rate was higher in females than males. The rate of change was similar in both time periods.
Hypertension
The prevalence of participants with an elevated blood pressure (those defined as hypertension-measured) significantly decreased over time, but the decrease was more significant in the first time period than in the second period for the overall cohort, in either sex and across all age groups. The proportion of participants on antihypertensive medications increased significantly over time. The mean values of systolic blood pressure dropped in all age groups in the first time period but increased slightly in period two. Detailed changes in blood pressure values over time for the whole group and comparisons of slopes are listed in the Table. Values separated by sex or age group are displayed in Appendix 1 and 2.
Hyperlipidemia
The mean TChol decreased during the first time period but the mild decline in the second period did not reach statistical significance, whereas LDL steadily decreased during both periods. Mean HDL showed a modest increase over time, but the slope was statistically significant only during the second time period, in line with the significant rise in the use of medications for dyslipidemia. 42 Triglycerides had a nonsignificant increase over both time periods and in all groups. Changes over time in the prevalence of dyslipidemia using different definitions and the corresponding slopes are listed in the Table. Values separated by sex or age group are displayed in Appendix 1 and 2.
Hyperglycemia and Diabetes
The rate of change for fasting glucose of all persons had a positive slope in the first time period (PϽ0.001), but in the second time period the change was insignificant. These trends were similar across sex and age groups. The rate of change for the percent of participants with diabetes mellitus had results parallel to those found for fasting glucose.
Smoking
The proportion of current smokers, cigarette, cigar, and pipe smokers all decreased over time in both sexes and age groups. The rate of change was more pronounced in the first time period than in the second for the whole sample. Although the proportion of 30-to 49-and 50-to 59-year-old cigar smokers dropped in the first time period, there was a slight increase in the rate of smokers in the second time period.
Cardiovascular Risk
The average age-adjusted 10-year CV risk between NHANES II and NHANES III decreased from 10.0% to 7.9% with a statistically significant slope (PϽ0.001; Figure 3 ). However, the average age-adjusted CV risk showed a smaller decrease between NHANES III and NHANES 1999 -2004 from 7.9% to 7.4%, (PϽ0.001). The slope between both periods was significantly higher in the first time period than in the second. (PϽ0.001). Trends were nearly identical when data were analyzed assuming that all participants were 50 years old.
When categorized by sex, CV disease risk in women decreased between NHANES II and NHANES III (PϽ0.001) but did not change between NHANES III and NHANES 1999 -2004 (Pϭ0.40). In contrast, men had a trend in CV risk similar to the entire sample ( Figure 4 ). People from 60 to 74 years of age were the only age group with a decrease in predicted CV disease risk of similar magnitude in both time periods ( Figure 5 ). For other age groups, the predicted risk decreased primarily between NHANES II and III but minimally between NHANES III and 1999 -2004. These trends persisted in our sex-adjusted analysis and analysis of patients assumed to be 50 years of age (data not shown).
Discussion
Our results, based on data from national surveys representative of the United States population, demonstrate that CV risk factors have changed at different rates and directions in the last 30 years. The net 10-year risk for incident CV disease in the United States has significantly decreased from 1976 -1980 to 1990 -1994, but has changed minimally thereafter. In women, there was no change in the latter period. Our results suggest that the stagnation of CV risk reduction can be explained by the slower improvement in lipid parameters and smoking rates, by the reversal of the trend in blood pressure control, and probably by the effect of the increased prevalence in obesity-related CV risk factors.
To the best of our knowledge, the current study is the first to calculate the trend in the net CV risk for developing CV disease over the last 3 decades. This period of time is when most evidence-based strategies for primary prevention of CV disease have emerged and been widely implemented. 17 These data have enormous public health implications, and suggest that the gain in primary prevention of CV disease that occurred from 1976 -1980 to 1990 -1994 has leveled off during the last time period, despite the discovery and implementation of effective treatment modalities in managing dyslipidemia and hypertension, 8, 32, 43 national antismoking campaigns, 44 and efforts related to primordial prevention. Our results also suggest that the lack of change of the net risk for incidental symptomatic CV disease may be attributable to the increased prevalence of obesity, 10, 11 which translates into a higher prevalence of diabetes mellitus 13,14 perhaps also contributing to the reversal of the trend in blood pressure control . The slope difference represents the difference between the 2 time periods. All slopes and slope differences are PϽ0.001 unless indicated otherwise. The number of cigarette, cigar, and pipe smokers may not add up to 100% because of patients who used multiple smoking modalities. The distribution of TGs were skewed, thus a natural log of triglycerides was used for significance testing.
History of hypertension indicates self-reported diagnosis of hypertension; hypertension on medications, participants with a self-reported diagnosis of hypertension and on anti-hypertensive medications; history of dyslipidemia diagnosed, participants with a self-reported diagnosis of dyslipidemia; dyslipidemia on medication, participants with a TChol Ն240 or an HDL Յ40 in males or Յ50 in females on medications; high cholesterol measured, participants with a TChol Ն240; dyslipidemia, participants with either a TChol Ն240 or an HDL Յ40 in males or Յ50 in females; dyslipidemia with TG, participants with a TChol Ն240 or an HDL Յ40 in males or Յ50 in females and a TG Ն150, only in the sample of participants with a morning subsample; diabetes, based on participants with self-reported diabetes or a fasting glucose level Ն126 mg/dL; total diabetes morning sample, prevalence on subsample of participants with only fasting blood glucoses; undiagnosed diabetes, participants with a fasting glucose Ն126 mg/dL and the absence of self-reported diabetes; current smoker, participants currently smoking cigarettes, cigars, or pipes; and cigarette smoker, participants currently smoking and that have smoked at least 100 cigarettes in their lifetime. *PϽ0.05. †PϾ0.05. ‡Based on 3463 patients from NHANES II, 4494 from NHANES III, and 7866 from NHANES 1999 to 2004. and the slower improvement in lipid parameters. If the obesity epidemic is sustained 45 and smoking rates, blood pressure, and lipid values continue with similar trajectories, the net population CV risk can be expected to increase. It is difficult to determine whether our results will translate into a larger number of cardiovascular events in the United States in the coming years. However, the predicted reduction in the 10-year risk for incident CV disease from 1976 -1980 to 1990 -1994 shown in the present report was consistent with the modest decrease in incident CV disease observed in surveillance studies comparing CV disease rates between the 80s and the late 90s. 46 This parallelism between the predicted reduction in risk and the reduction in events Ϸ10 years later adds validity to our results.
Several studies have assessed temporal changes in individual CV risk factors, and their results have been for the most part similar to ours, despite the fact that our analysis was limited to those without history of coronary disease or stroke and excluded young adults or those older than 74 years. 2, 3, 8, 10, 13, 47 Our results confirm the previous observation that the early declines in adult smoking rates might be halted. 3, 4 This study also agrees with others demonstrating the increased prevalence of cigar smoking in the last decade, 45 which may explain the minimal reduction of overall smoking during the latter period, compared to the first time period.
Hajjar commented in 2003 that the prevalence of hypertension might be increasing despite a prior analysis from NHANES, suggesting hypertension prevalence was declining. 8 Our results support the concept that hypertension has had a bidirectional trend over the last 30 years, manifested by a decline in systolic blood pressure values from NHANES II and NHANES III and a rise in these values between NHANES III and NHANES 1999 -2004, despite better rates of awareness and wider use of antihypertensive medications.
Other reports have described the secular trends in serum lipids from 1960 to 2002, demonstrating that mean TChol and LDL levels have steadily decreased without significant changes in HDL and serum TG levels. 2 Conversely, our results illustrate a modest secular increase in HDL, particularly between 1988 -1994 to 1999 -2004. Several factors may have contributed to lipid parameter improvement, including enhanced screening for dyslipidemia and higher use of medications for dyslipidemia, which can decrease TChol and LDL but also raise HDL. Dietary changes, particularly a reduction in saturated fat intake with mild increases in monounsaturated fat intake, may also explain the increase in mean HDL. Because exercise levels have remained unchanged, 48, 49 the modest improvement in HDL could not be attributed to changes in physical activity.
Several studies have highlighted the increased prevalence of diabetes mellitus since 1976, particularly diagnosed diabetes, with little change in the prevalence of undiagnosed diabetes. 13, 50 Our analysis also shows a significant increase in the average fasting blood plasma glucose levels over time, suggesting that the increase in the prevalence of diabetes mellitus reported elsewhere is not positively confounded because of changes in diagnostic criteria.
The limitations of the current study relate primarily to the intrinsic limitations of the NHANES surveys and that of the Framingham prediction model. As in any survey, participation bias may have yielded a sample that is not entirely representative of the population. However, specific to NHANES is that the nationally represented population excluded participants residing in nursing facilities, members of the armed forces, institutionalized participants, or nationals living abroad. Hence, generalizing the results to these populations should be done with caution. The survey was designed specifically to oversample certain subgroups of public health interest to increase the reliability and precision of health estimates for these groups. In addition, excluded patients may have differed from those included in this study. Some measurements may have differed by survey stage, and our efforts to standardize values might not be able to create identical variables. We acknowledge that many NHANES variables, including those assessing CV disease, are selfreported and may lead to reporting bias. The definitions of diabetes and current smoking in the Framingham study were slightly different than the definitions used in the current analysis. Finally, although the Framingham risk score was developed for people with no history of CV disease, a small fraction of the total sample might have failed to report history of CV disease and were included in the current analysis.
Although several of these limitations may hamper the validity of risk estimates in each NHANES survey, these potential sources of bias and error were present in the three surveys. Therefore, the comparison of trends in risk may be less affected than the individual risk estimates.
Our analysis has several strengths. Contrary to other reports addressing the change in several CV risk factors, we used widely validated risk scores to predict the risk of incident symptomatic CV disease. By measuring the net change in CV risk, we can better estimate the global impact of preventive strategies, particularly when certain risk factors improve, others do not change, and others worsen during the same time period. NHANES data were obtained using a prospective methodology with standardized measurements and definitions, and are known to be representative of the US population. Risk functions derived from NHANES data have accurately projected the extent of CV events and overall mortality even in other population groups. 51, 52 Furthermore, only 1 other study has evaluated the change in CV risk among United States adults but only used 2 NHANES surveys, and relied on the risk model adopted by the National Cholesterol Education Program Adult Treatment Panel III and not the precise Framingham formula in estimating overall CV disease risk, and their results were not age-stratified. 53 The Framingham risk score does not account for risk factors such as family history of premature coronary disease, exercise, diet, obesity, or body fat distribution. Nevertheless, at the time the scoring system was developed, exercise, obesity, and diet were believed to impact and mediate CV risk through factors already included in the model. Hence, our findings may actually be conservative risk estimates, as the increasing prevalence of obesity may have led to higher CV risk, not only mediated through commonly recognized cardiac risk factors, but also via obstructive sleep apnea, high leptin and low adiponectin levels, and changes in other inflammatory cytokines and adipokines linked with central obesity. 54 Additionally, the Framingham risk score was created to help clinicians identify patients at high risk for CV disease, and therefore simplicity has been a priority even if that requires sacrificing a small incremental predictive value with the use of the other risk factors.
The Framingham risk score was derived from a community sample of white subjects, whereas the population included in NHANES overrepresents minorities. The validity of Framingham and other scores predicting CV disease has been tested in diverse populations and shown different event rates for any given estimated risk value. Although this weakness has been addressed and can be partially corrected by doing appropriate calibration, 21 the validity of the overall estimated risk may be limited. Moreover, CV risk prediction rules can help to predict changes in event rates after changes in different CV risk factors occur. For example, in an analysis showing the change in predicted CV risk in a sample of patients who underwent bariatric surgery, 51,55 the predicted reduction of cardiovascular events was very close to the risk reduction subsequently reported in a prospective cohort of people who underwent bariatric surgery. 52 It has also been shown that the use of risk factor categories provides similar prognostic information as using noncategorical prediction functions. The score uses blood pressure and lipid values regardless of history of diagnosis or medical treatment for hypertension or dyslipidemia, respectively. Blood pressure and cholesterol values regardless of use of medications better capture the impact of public health and clinical factors that may change over time, and are also less susceptible to recall bias than definitions based on treatment status. The prognostic performance of Framingham could affect the absolute risk estimates but not the trend over time because the same limitations will apply to the 3 time periods. Therefore, our main findings and conclusions are not hampered by the limitations inherent to the Framingham risk score.
In conclusion, our study has shown that the estimated net risk for CV disease in the United States population decreased from 1976 -1980 to 1988 -1994, but has changed minimally from 1988 -1994 to 1999 -2004. The net CV risk has remained unchanged in women from 1988 to 1994. Cardiovascular risk reduction has been maintained in patients aged 60 or greater, but the difference in risk reduction observed from NHANES II and III has been minimal in younger people, especially among those age 30 to 39. The increase in the prevalence of diabetes and in blood pressure levels may explain the staggering of the risk reduction from NHANES III to NHANES 1999 -2004. Because obesity may predispose to diabetes mellitus 14 and can aggravate systemic blood pressure and dyslipidemia, the attenuation in risk reduction can be at least partially attributed to the growing epidemic. However, other factors like the attenuation in the reduction of prevalent smoking and cholesterol control observed in the second time period compared to the first one might also explain the results. These results reinforce the need for aggressive community-wide and office-based promotion of primordial prevention, with emphasis on physical activity, exercise, dietary changes aiming for a higher intake of fruits and vegetables, lower intake of salt and saturated fat, maintenance of a healthy weight and smoking control. These results also underscore the key role of health care providers managing CV risk factors. These findings also confirm that the discovery and use of effective medications for lipids and blood pressure do not translate into global risk reduction, unless they are paired with strategies preventing the occurrence of diabetes, hypertension, and dyslipidemia and reducing the rates of new smokers.
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